🟢 Alzamend Neuro is trading 5.7% up in pre-market with no clear company-specific catalyst identified

Alzamend Neuro is trading 5.72% up at $1.41 in pre-market on October 2, 2026, with no clear company-specific catalyst identified.

• The move follows a sharp decline in the October 1 session and a reported after-hours rebound.
• Its investor-relations press-release page lists September 16, 2026, as its latest announcement, with no new release explaining the move.
• Broader U.S. futures are modestly higher, while the biotech sector is lower; available evidence does not establish a sector or market-wide explanation.